The FDA Has Reassigned Prescription Drug User Fee Act Date For Bristol Myers Squibb's Subcutaneous Formulation Of Opdivo (Nivolumab) Across All Previously Approved Adult, Solid Tumor Opdivo Indications. The Updated Goal Date Is December 29
Portfolio Pulse from Benzinga Newsdesk
The FDA has reassigned the Prescription Drug User Fee Act (PDUFA) date for Bristol Myers Squibb's subcutaneous formulation of Opdivo (Nivolumab) for all previously approved adult, solid tumor indications. The new goal date is December 29.
May 21, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has updated the PDUFA date for Bristol Myers Squibb's subcutaneous formulation of Opdivo to December 29. This regulatory update could impact the stock price as investors anticipate the FDA's decision.
The reassignment of the PDUFA date indicates that the FDA is still in the process of reviewing the subcutaneous formulation of Opdivo. This could lead to increased investor interest and potential stock price movement as the new goal date approaches.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100